• Known pregnancy or planning to become pregnant during the study period • Currently breastfeeding • Known maculopathy or retinal disorder. • Known cardiac disease/dysrhythmia or prolonged QTc • Know renal disease • Known hepatic disease • Known hypomagnesaemia or hypokalaemia. • Currently using hydroxychloroquine or any 4-aminoquinoline. • Use of medications prolonging QTc including: Class IA (quinidine, procainamide, disopyramide) and III (amiodarone, sotalol, ibutilide, dofetilide) antiarrythmics, macrolides, methadone, fluoroquinolones, domperidone, fluconazole, ondansetron, tacrolimus, tramadol, anti-retrovirals. • Current use of tamoxifen, digoxin, tricyclics, SSRIs, antipsychotics, halfantrine, cyclosporin and anti-epileptic medications • Current use of oral hypoglycaemics including glipizide, glyburide, gliclazide, glimepiride, repaglinide, nateglinide, metformin, rosiglitazone, pioglitazone, acarbose, miglitol, voglibose, sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, dapagliflozin, canagliflozin, bromocriptine. • Sensitivity or allergy to 4-aminoquinilone compounds or any excipients used in the study • Unable to access digital consent forms or maintain remote contact with the study team • Have any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.

• Known pregnancy or planning to become pregnant during the study period • Currently breastfeeding • Known maculopathy or retinal disorder. • Known cardiac disease/dysrhythmia or prolonged QTc • Know renal disease • Known hepatic disease • Known hypomagnesaemia or hypokalaemia. • Currently using hydroxychloroquine or any 4-aminoquinoline. • Use of medications prolonging QTc including: Class IA (quinidine, procainamide, disopyramide) and III (amiodarone, sotalol, ibutilide, dofetilide) antiarrythmics, macrolides, methadone, fluoroquinolones, domperidone, fluconazole, ondansetron, tacrolimus, tramadol, anti-retrovirals. • Current use of tamoxifen, digoxin, tricyclics, SSRIs, antipsychotics, halfantrine, cyclosporin and anti-epileptic medications • Current use of oral hypoglycaemics including glipizide, glyburide, gliclazide, glimepiride, repaglinide, nateglinide, metformin, rosiglitazone, pioglitazone, acarbose, miglitol, voglibose, sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, dapagliflozin, canagliflozin, bromocriptine. • Sensitivity or allergy to 4-aminoquinilone compounds or any excipients used in the study • Unable to access digital consent forms or maintain remote contact with the study team • Have any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.